북미 정신과/우울증 약물유전학 테스트 시장 – 2029년까지의 산업 동향 및 예측

북미 정신과/우울증 약물유전학 테스트 시장 분석 및 통찰력

약리유전학 검사는 사람이 약물을 어떻게 대사하는지에 대한 정보를 제공하여 의료 전문가에게 도움이 됩니다. 이 정보는 의사와 다른 사람들이 바람직하지 않은 결과를 초래할 수 있는 항우울제를 처방하는 것을 피하는 데 도움이 될 수 있습니다. 약리유전학은 주요 우울 장애(MDD) 치료에서 항우울제 반응과 내약성을 예측하는 데 유망한 것으로 나타났습니다. 약리유전학은 항우울제 선택과 복용량을 안내하여 임상 결과를 개선할 수 있습니다. 성장하는 생명공학 분야와 증가하는 의료 지출은 정신과/우울증에서 약리유전학 검사에 대한 수요를 가속화했습니다.

암 질환의 유병률 증가, 우울증 및 기타 정신 질환 치료의 새로운 기술로 인해 정신과/우울증 장비 및 시술에서 약물유전학  검사의 채택이 증가하고 있으며, 비수술적 시술에 대한 선호도가 높아지는 것이 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다. 그러나 검사와 관련된 높은 비용, 엄격한 규제 및 인식 부족으로 인해 예측 기간 동안 정신과/우울증에서 약물유전학 검사 시장 성장이 방해받을 것으로 예상됩니다.

Data Bridge Market Research는 북미 정신과/우울증 약물유전학 검사 시장이 2029년까지 9억 8,128만 달러에 도달할 것으로 예상하고 있으며, 예측 기간 동안 CAGR은 9.7%입니다. 불안은 북미 인구의 우울증 비율이 증가함에 따라 시장에서 가장 큰 유형 세그먼트를 차지합니다. 이 시장 보고서는 또한 가격 분석, 특허 분석 및 기술 발전에 대한 심층적인 내용을 다룹니다.

North America Pharmacogenetics Testing in Psychiatry/Depression Market Definition

Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.

The terms personalized medicine, stratified medicine, and precision medicine are close relatives of pharmacogenetics, but these are broader terms that also cover additional non-genetic factors. Nevertheless, pharmacogenetics is an important component of these areas. Pharmacogenetics is primarily concerned with human germline DNA variation, but there have also been important recent advances in understanding mood disorders, and mental illnesses.

Pharmacogenetics testing studies the interaction between drug and gene response of a person and searches for the gene variation which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights which subsequently be used to develop customized or personalized medication.

North America Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER

Depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Depression can become a serious health condition of mild to extreme severity, affecting the person to suffer greatly and can lead to suicide in the worst cases. Although over 45 antidepressants are available, suboptimal response poses a challenge and is considered a result of genetic variation, psychiatry/depression. Depending on the severity and pattern of depressive episodes over time, healthcare providers may offer psychological diagnosis such as behavioral activation, cognitive behavioral therapy, interpersonal psychotherapy, and/or antidepressant medication such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Different drugs are used for this kind of mental disorder.

With the growth in the prevalence of depression, the demand for pharmacogenetics testing is also increasing as it studies the effect of genetic variants intending to furnish tailored diagnosis. The market is expected to grow in foresting period.

• RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE

Pharmacogenetics test aids the medical professional in choosing the best medicine for the person because the test searches for the gene variant that may be responsible for influencing the effect of the drug.

Medicine is beginning to get personal, and patients are gradually expressing interest in improved outcomes and less adverse effects with personalized medications. Personalized medicine has the potential to tailor the therapy with a high safety margin and the best response. This trend is largely driven by genome sequencing improvements.

The move toward personal healthcare means changes in the manufacturing of medicines. Manufacturers are moving from creating small molecules to the combination of small molecule and gene therapies. Sponsors focus on replacing inefficient large-scale batch production with investment in new technology and producing personalized drugs.

Restraint

• Lack of skilled Medical and genomic expert 

Most clinicians still lack confidence in pharmacogenetic (PGx) testing and subsequent data interpretation, indicating insufficient knowledge in this field. It emphasizes the need to improve literacy among healthcare professionals regarding expertise in and understanding of pharmacogenetic (PGx) testing.

Lack of practitioners awareness about the possibilities of pharmacogenetics and poor or insufficient explanation of the test results also reduce personalization technologies for patients. In addition to developing thematic training courses at medical universities, including the educational cycles in continuing professional education systems, and free placement of information for practicing doctors are required: academic internet portals, webinars, etc. A clinical pharmacologist plays a crucial role in the implementation of pharmacogenetic testing.

The competence of a clinical pharmacologist in the field of pharmacogenetics is critical: he or she is the one who organizes the application of genotyping in clinical practice, interprets tests, and informs doctors about the possibilities of pharmacogenetics for patients with specific nosologies, that is, acts as the main link between the scientific world, the healthcare system and practicing physicians in the process of introducing pharmacogenetics.

Opportunity

• Rising advancements in technology

Advances in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice for psychiatric disorders. Personalized medicine may be defined as a comprehensive, prospective approach to preventing, diagnosing, treating, and monitoring disease in ways that achieve optimal individual health care decisions. Over 100 medications now contain United States Food and Drug Administration (FDA) labelling related to potentially applicable pharmacogenomic biomarkers with technological advancements in healthcare. Also, new and advanced methods are being developed to promote pharmacogenetics testing in depression-like disorders. These tests use advanced genetic testing methods to give precise results to form a treatment regimen. The improvements in technology supporting tests improved accessibility of testing options, and the growing number of resources that help clinicians understand how to use this information when it is available are making this aspect of personalized or precision medicine a reality. Thus,  providers need to become more aware of the scientific and clinical relevance of pharmacogenomic tests.

The tests also help to establish a meaningful relationship between a drug and the individual genetic makeup. This helps in deciding the drugs to be administered to the patient to treat major depressive disorders and other psychiatric conditions.

Challenge

• Strict government regulation on new products and instruments approval

The concerns regarding the efficacy and safety of products have caused most governments to develop regulatory agencies and policies to look after the development of new medical products or tests. The use of these medical products can be done after passing stringent regulatory standards, which ensure the product is safe, well studied, and has no adverse reactions.

The recent guidelines and the amendment have adequate guidance for manufacturers. International regulations such as food, drug, and administration play a major role in the new launch of medical products or test into the market. Thus, it can be a major restraint for the market. Therefore, strict government regulation on new products and instrument approval will likely impact the market.

Post-COVID-19 Impact on North America pharmacogenetics testing in psychiatry/depression market

The COVID-19 outbreak had a beneficial impact on the expansion of the pharmacogenetics testing industry. The pandemic has had a negative impact on the pharmacogenomics market growth on account of the temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers. Since the second half of 2020, with the rising demand for research on certain drugs and testing kits for COVID-19, pharmacogenomic practices have been in vogue.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Developments

• In April 2022, Blue Care Network (BCN) launched a precision medicine program, Blue Cross Personalized Medicine, which leverages pharmacogenomics, or genetic testing, to personalize and tailor medication treatments more effectively for select members based on a review of their prescribed medications for various diagnosis including behavioral health, cardiology, cardiovascular, and oncology. OneOme LLC has helped BCN achieve its precision medicine program goals and reduce the total cost of care and improve patient health outcomes by reducing adverse drug reactions. This has helped the company to enhance its product portfolio.
• In February 2022, PacBio, a leading provider of high-quality, highly accurate sequencing platforms, announced that it is supporting The Hospital for Sick Children (SickKids) in Toronto, Canada, in using HiFi whole genome sequencing (HiFi WGS) to potentially identify genetic variants that may be associated with medical and developmental conditions. Samples that are examined using HiFi WGS were previously sequenced using short-read DNA sequencing technology but still lack the identification of a disease-causing variant. This has helped the company to enhance the use of its products.
• In July 2022, according to a new nationwide study of nearly 2,000 veterans conducted by the U.S. Department of Veterans Affairs (VA), and Major Depressive Disorder (MDD) remission rates were significantly improved when clinicians had access to GeneSight Psychotropic test results from Myriad Genetics, Inc. in largest ever mental health PGx randomized controlled trial. This has helped the company to show its progress in pharmacogenetic testing.
• In January 2021, myDNA Life Australia Pty Ltd, announced a merger with the U.S., Houston-based consumer DNA test company, FamilyTreeDNA, and its parent company, Gene by Gene, for revolutionizing the field of pharmacogenomics, making truly personalized medicine a reality before expanding into nutrigenomics to deliver actionable, personalized nutrition, fitness and skincare recommendations. This has helped the company to expand its business.

 North America Pharmacogenetics Testing in Psychiatry/Depression Market Scope

North America pharmacogenetics testing in psychiatry/depression market is segmented into type, test type, gene type, patient type, product, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Type
  • Anxiety
  • Mood Disorders
  • Depression
  • Bipolar Disorders
  • Psychotic Disorders
  • Eating Disorders

On the basis of type, North America pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type
  • Whole Genome Sequencing
  • Chromosomal Array-Based Tests

On the basis of test type, North America pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Gene Type
  • CYP2C19
  • CYP2C9 AND VKORC1
  • CYP2D6
  • HLA-B
  • HTR2A/C
  • HLA-A
  • CYP3A4
  • SLC6A4
  • MTHFR
  • COMT
  • OTHERS

On the basis of gene type, North America pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type
  • Child
  • Adult
  • Geriatric

On the basis of patient type, the North America pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By Product
  • Instruments
  • Consumables
  • Software & Services

On the basis of product type, North America pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services.

• North America Pharmacogenetics Testing In Psychiatry/Depression Market, By End User
  • Hospitals & Clinics
  • Dignostics Laboratories
  • Academic And Research Institutes
  • Others

On the basis of end user, North America pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others.

• 북미 약물유전학 테스트 정신과/우울증 시장, 유통 채널별
  • 직접 입찰
  • 제3자 배포
  • 병원 약국
  • 기타

북미 정신과/우울증 약물유전학 검사 시장은 유통 채널을 기준으로 직접 입찰, 제3자 유통 병원 약국 및 기타로 구분됩니다.

북미 정신과/우울증 시장 약물유전학 테스트 지역 분석/통찰력

북미 정신과/우울증 약물유전학 검사 시장을 분석하고, 유형, 검사 유형, 유전자 유형, 환자 유형, 제품, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다. 이 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.

2022년에는 북미가 GDP가 높은 가장 큰 소비자 시장에 주요 시장 참여자가 존재하기 때문에 우세합니다. 미국은 약물유전학 검사의 기술 발전으로 인해 성장할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 북미 약물유전학 테스트 정신과/우울증 시장 점유율 분석

정신과/우울증 시장에서 북미 약물유전학 검사의 경쟁적 환경은 경쟁업체의 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 포함됩니다. 위에 제공된 데이터 포인트는 정신과/우울증 시장에서 북미 약물유전학 검사에 대한 회사의 초점과만 관련이 있습니다.

정신과/우울증 시장에서 북미 약물유전학 테스트 분야에서 활동하는 주요 업체는 다음과 같습니다.

• Genelex (Invitae 법인의 일부)
• Genewiz (Azenta Life Sciences의 일부)
• MD 랩스
• 주식회사 바이오제네이큐
• ONEOME, 유한회사
• 미리어드 제네틱스 주식회사
• 젠시스
• 캐슬 바이오사이언스 주식회사
• 팩바이오
• 퀴아젠
• 써모 피셔 사이언티픽 주식회사
• AB-바이오틱스.SA 
• 코리엘 라이프 사이언스
• 유로핀스 사이언티픽
• 일루미나 주식회사
• 다이내믹 DNA 연구소
• 스타다팜 GmbH
• 색상
• CNS도스
• 제노마인드 주식회사
• 헬스스펙
• myDNA 라이프 오스트레일리아 유한회사
• 허드슨알파
• 소닉 헬스케어 리미티드

연구 방법론: 북미 정신과/우울증 시장에서의 약물유전학 테스트

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.

SKU-60339